Under 10% of individuals who could benefit from GLP-1 drugs such as Wegovy have access to them, caution the WHO as it releases its initial advice on the drugs.
Considering more than one billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to these injectable treatments.
According to forecasts, more than two billion are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidance recognises that obesity is a long-term condition that can be managed with holistic and ongoing support," said its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major barriers to widespread availability to the jabs that can assist patients in reducing substantial body mass, notes the body.
GLP-1 Therapy Shortage
Even in the current best projected scenario, the production of these medications would only suffice for approximately 100 million people – under 10% of eligible patients, per the WHO.
The advice encourages nations and manufacturers to increase access, by approaches like voluntary licensing.
Exclusive production rights on a key compound – the primary component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Drugs Operate
The injections mimick a natural hormone to delay gastric emptying, curb appetite and increase feelings of fullness so users consume fewer calories.
Patients usually see weight reduction after several weeks of starting on the weekly injections.
Studies points to patients may see weight return after a year of halting the medication, as their normal food cravings come back.
To be above a healthy weight raises your likelihood for developing health problems, including diabetes, heart disease, stroke, and specific cancers.
Obesity concerns people in every country and was associated with millions of deaths worldwide in 2024, according to the health agency.
